New Pieces Of Evidence Are Reported in Demand With The Use Of Natural Compounds 2
Oct 14, 2022
Please contact oscar.xiao@wecistanche.com for more information
6. Combined Synergistic Effects of Polyphenol Management
Synergistic therapeutic effects occur or manifest themselves using a combination of (at least) two polyphenols. For example, two polyphenols combined (resveratrol and quercetin) substantially encourage the percentage of senescent cells in cultured glioma cells than through single-use [124]. The anti-cancer effects of traditional chemical treatments and therapeutics have also been enhanced by polyphenols. Resveratrol enhanced temozolomide-induced senescence and further lowered glioma cell temozolomide resis-tance[132]. Additionally, resveratrol showed that the cancer cell resistance to paclitaxel can be re-sensitized and the gefitinib resistance of non-small cells of the lungs can be overcome by increasing the fitting intracellular concentration when used along with gefitinib [133].

The treatment with resveratrol also led to more DNA breakdowns and production of reactive oxygen species(ROS), which enriched ionized radiation premature senescence and reduced radioresistance in lung cancer cells [134]. The combination scheme resistant to doxorubicin has allowed doxorubicin-resistant gastric cancer cells to recover their sensitivity to the drug, reverse an epithelial-mesenchymal transition, and promote apoptosis in cells in vitro [135]. Eleven of these cases involve the polyphenols' brilliant role in medicinal/radioresistant stubborn cancers. Potential anti-tumor effects of resveratrol are summarized in Figure 3.

The polyphenolic compounds are commonly included in the human diet, and recent results suggest that neurofibromatosis 1 has been successful in the treatment of patients by combining turmeric and the Medellin diet, a dietary pattern rich in polyphenols [136]. cistanche stem Combination therapy with resveratrol and other polyphenols may enhance the effects of the treatment applied to the patient and may decrease the resistance of cancer cells while increasing the effectiveness of clinical therapy with radiation or drugs.
7. Resveratrol Clinical Trials and Therapeutic Potential
Note that the resveratrol doses used in the cell cultures and the in vivo concentrations are often distinguished. For example, various studies showed that resveratrol has a signaling effect of 10μM to 100 uM on used concentrations 【95】. On the other hand, the median plasma level of resveratrol was just 25 mg of resveratrol equal to high rotten wines and 2.4 μMin humans, with a5g transition dose【137】. When lower levels are added to cells, the outcomes are unpredictable, often without any effects[138]. Particularly,2-3 orders of magnitude exceed the dietary doses of resveratrol in supplements are also available in various trials【139】. The plasma levels are 2-18 μM with one dose of resveratrol 【140】. Eight weeks of intake of 3 g daily in obese people have led to fast and extensive resveratrol conjugation[141]. The research duration ranges from acute exposure to several days of exposure up to one year [14,142,143]. Resveratrol is given to people for a period of 1-3 months, in most trials. The relatively short duration of the trials raises some difficulties, s therapeutic, but not preventive, studies are needed. Research to prove that resveratrol is preventative should be performed for at least one year without taking account of practical and economic iSSues.

Cistanche can anti-aging
These trials are costly and not readily funded, but would gain useful information about the preventative/therapeutic potential of resveratrol [138]. Resveratrol studies in people with single/multiple daily doses (of up to 600 mg/day for two to three days)have demonstrated that resveratrol is safe in the test conditions; it was also revealed that the most important metabolites in the circulation of resveratrol are R3S, R4 G, and R3 G with especially high levels of sulfur conjugation [137,144,145]. Before 2010, several phase 1 clinical studies focusing on pharmacokinetics were conducted, but since then the number of clinical studies that have examined the bio-effect of resveratrol has substantially increased. It is a recognized the fact that resveratrol is effective in human medicine, in recent years, for several pharmacological properties [146]. Clinical trials below briefly describe the main findings and results regarding the potential of resveratrol in cancer.
7.1.Clinical Trial 1
Resveratrol for patients with colon cancer: The first clinical trial for resveratrol in cancer patients is a study of Nguyen's on biomarkers, investigating the expression of different components and target genes in a Wnt way. Two patients received resveratrol in doses of 20mg/day,80 mg/day on the 3rd and 4th day, and 160 mg/day on the 5th and 6th day. All the patients were given mixed extracts 125 mg/day and an 8 oz glass of wine. No dose adjustments were made to avoid side effects associated with resveratrol in patients. As a result, Wnt genes, D1 cycling, and axin expression, combined with other bioactive ingredients, in the normal colonic mucosa, with a small dose of resveratrol, were inhibited, which shows that resveratrol-related inhibition of the Wnt pathway can help prevent colon cancer [147,148].
7.2.Clinical Trial 2
A biological study of resveratrol effects: Winslow of the University of Wisconsin, Madison, performed a biological study on the effect of resveratrol on topics of low-level gastrointestinal cancer. The activation of Notch-1, which prevents the growth of tumor cells, is shown to be determined by resveratrol. In this study, the effects of resveratrol and Notch-1 on tumor tissue and the tolerances of persons taking resveratrol for up to three months with neuroendocrine tumors (5 g a day, administered orally in two doses of 2.5g each, with a minimal limiting dose according to the standard toxicity criteria of the National Cancer Institute) were investigated. Concentrations of the tumor markers were compared with post-treatment concentrations (e.g., chromogranin, 5-HIAA, gastrin). The response of the tumor was determined every 3 months. Additionally, the standard Response Assessment Criteria for Solid Tumors (RECIST)would be used for recording the response levels of the tumor.
7.3. Clinical Trial 3
Resveratrol and human hepatocyte function in cancer: The phase I bio-marker analysis was carried out by Randall Holcombe of the University of California, Irvine. The study aimed to determine the minimum levels of fresh red resveratrol-rich grapes needed to show signs of colon cancer prevention. cistanche tubulosa benefits and side effects The grape diet provided a low dose of resveratrol in combination with other potentially active ingredients in grapes. Small flexible sigmoidoscopies of colon tissue were collected before and after the ingestion of the red grape diet. Various doses have been received(1 or 2/3 or 1/3 lb/day of red fresh grapes). This work on Wnt biomarkers and essential data on the efficacy of this dietary strategy in the management of colon cancer has demonstrated the effects of low-dose resveratrol extracted from grapes.

7.4. Clinical Trial 4
Biomarker study for resveratrol in colon cancer prevention: The randomized, two-blind, placebo-controlled, inpatient and outpatient trials are results from"a clinical trial in which health, drug kinetics and drug pharmacodynamics of SRT501 are assessed in subjects with colorectal cancer and hepatic metastases."In patients with colorectal cancer scheduled for hepatectomy, micronized resveratrol (SRT501)was administered in a 5 g daily intake for 14 days. Micronization permits greater absorption of resveratrol, thus increasing the availability of SRT501. Mean plasma resveratrol levels were 1.9± 1.4 ng/mL at a single dose of SRT501, above the recorded levels of non-mice resistant resveratrol at equivalent doses 2- to 3.5-fold [15]. Resveratrol was seen in hepatic tissue after administration of SRT501. In malignant hepatitis, the precursor of apoptosis caspase-3 was significantly increased by about 39% in comparison with the tissue of placebo-treated patients following SRT501 [149].
7.5. Clinical Trial 5
Treating post-surgery patients: Pilot research on resveratrol in poor glucose tolerance elderly adults. cistanche tubulosa extract The study analyzed its effect on post-meal glycemic metabolism. This proposed pilot research recommended the administration of resveratrol (as treatment:500 mg capsules(totally 1500 mg)orally, twice a day, for six weeks) in old adults, suggesting that it will reduce tolerance [150].
7.6. Clinical Trial 6
Prevention in healthy patients: The study aims to explore the impact of different doses of resveratrol (75 mg or 150 mg/day on the health of the heart and blood vessels). Results suggested cardiovascular and restorative safety in elderly generations. This resVida study phase 1/2 took place over 12 months, in 90 overweight/obese people over 50 years of age (30 in each group)[151].
7.7.Clinical Trial 7
Pharmacokinetic and pharmacodynamic parameters metabolic syndrome and resveratrol: In order to enhance the symptoms of metabolic syndrome, the researchers considered confirming resveratrol effects after being administered under controlled weight stability conditions, standard diet, and strict observance of treatment; it decreases the risk of diabetes and heart disease [152].

7.8. Clinical Trial 8
Healthy adults: Phase 1 studies did not support nephrotoxicity in metastatic colorectal patients. As SRT501 is highly metabolic, many myeloma patients are at risk for renal failure due to many factors. A total of 24 patients were enrolled in phase 2, chronic myeloma clinical trials with recurred patients, with/without bortezomib and 5 g SRT501, or with a minimum of one prior refractory therapy. For patients included in the research, the activity and safety of SRT501 alone or combined with bortezomib were evaluated [149,153]. Bortezomib stabilization may have avoided renal failure, but inadequate effectiveness(with nausea and vomiting) may cause dehydration and advanced renal failure. Renal toxicity was observed in 5out of 24patients. Renal dysfunction is one of the multiple myeloma clinical signs and it has been identified in nearly half of the patients with the disease. For patients who have recurred/refractory multiple myeloma, this study has shown an unacceptable health profile, poor efficacy, and the risks of new drug production [154].
7.9. Clinical Trial 9
Postmenopausal woman: Resveratrol could potentiate inhibition of cell proliferation based on simvastatin and inhibit the mevalonate cycle, indicating new action mechanisms and emphasizing the potential translation and clinical significance of this micro component interaction with simvastatin [142. A phase 4 clinical assessment is being carried out in Poland, on the effects of simvastatin and micronized trans-resveratrol on polycystic ovarian syndrome (PCOS). The effects of simvastatin (20 mg daily) and micronized trans-resveratrol on polycystic ovary syndrome are studied in both endocrine and metabolic disorders. cistanche tubulosa reviews Assessments take place based on the therapy lasting three to six months, and the key effect is an improvement in serum total testosterone and strong insulin levels. Dr. Frank Gonzalez, principal investigator, Director of Endocrinology and Infertility Division at Indiana University, believes that the use of human chorionic gonadotropin (HCG) in females with PCOS induces excess ovarian androgens, that dairy cream intake enhances the activation of the white cell, and that the HCG-similar relationship occurs [142]. For three years, thirty women with PCOS(10 average weight, 10 overweights, with increased abdominal adiposity, 10 obese), and 30 women with ovulatory inspection(10 average, usually abdominal, 10 overweight, and 10 obese) were observed. The researcher also believes that the ovarian androgenic responses to HCG and inflammation responses to the consumption of dairy cream will be reduced, the adiposity reduced, the sensitivity to the insulin increased and the ovulation of average-weight women with PCOS decreased over 12 weeks. Salsalate was given in a group of 16 women, 8 with PCOS(four with usual adiposes in the abdomen and four with increased abdomen adiposity) and 8 PCE (four with regular adiposity in the abdominal area, four with normal adiposities in the abdomen) for 3 years. This pilot project helps to decide whether a massive, double-blind, randomized study of PCOS women will further test the above hypothesis [142].
Figure 4 summarizes the clinical evidence of resveratrol's preventive effects on human health, especially in cancer. Only 10 of them (50 percent) were completed based on the above reports.
The primary aim is to assess the dosage and side effects in clinical trials, in step 1 Eight of the clinical trials relate to various cancer types and show a preventive action of resveratrol. Furthermore, we suggest improving the quality of clinical trials for prospective patients through the appropriate designs, new formulations, and/or routes of administration, and biomarkers. Unfortunately, currently, the prevention and therapeutic effect of resveratrol only occur in vitro and in vivo model organism studies.

8. Adverse Effects
Resveratrol is normally well-tolerated, based on animal tests, and very few trials have been carried out in human cases of short or acute exposures. If eight healthy people were exposed to resveratrol twice a day for 8 days, six in eight people presented mild diarrhea, typically in the early part of the 8-day therapy period [155]. For the randomized, placebo-controlled analysis, two adult patients (men and women) healthy volunteers per group of 25, 50, or 150, received up to six times a day,975 mg/day. Both groups had moderate and related adverse effects. Relatively high doses and a short period of administration have been used for resveratrol over time, however, relatively low plasma resveratrol levels have been produced [102]. Treatment with up to 270 mg resveratrol to 19 volunteers for one week did not cause pain [156].
In an exposure check of seven days, Elliott et al.reported that healthy participants tolerated resveratrol well, but experimental specifics were not presented and results were difficult to determine[157]. In the same article, a study with daily administration of 2.5 g or 5 g resveratrol for 28 days was briefly mentioned. The writers reported the general nature and reversibility of adverse events but did not provide experimental detail for a closer assessment [157]. In 20 patients receiving 0.5 g or 1.0 g resveratrol daily, there was strong tolerance eight days before the procedure [158].
9. Recommendations, Challenges, Future Perspectives, and Concluding Remarks
The first international conference on resveratrol and health in Denmark in September 2010, Resveratrol 2010, assessed the existing knowledge on the topic and offered guidance for usage and potential resveratrol studies. One of the main subjects at the congress was that numerous ways of determining whether the dosage or biomarker could characterize the drug may lead to the beneficial effects of resveratrol, making it difficult to decide [159,160]. Resveratrol 2012 (2nd edition of the International Conference on Health and Resveratrol)found that the proof submitted for clinical studies is not adequate to support the chronic clinical resveratrol intake recommendation at the University of Leicester, England. New animal data and new clinical trials are promising, and demonstrate the need for future research. Longer exposure to resveratrol has been suggested in new trials during the third International Resveratrol and Safety Conference, in Hawaii, 2014. No true clinical trials have been published to date investigating resveratrol in cancer [161].
Cancer refers to a condition characterized mainly by uncontrolled cell growth. cistanche UK The diagnosis of cancer is the main challenge for doctors in the field. If the diagnosis is late, classifying cancer as being in the fourth stage, metastases are usually triggered, and the recovery rate will obviously be low, with extremely low chances of curing the patient. Therefore, in this last stage, the success rate with the use of resveratrol (as a type of treatment or adjuvant in treatment) cannot be ensured.
Combination therapy and the synergistic approach are and must be further studied through various research. As presented in the previous material, it has been found that the combined treatments have additionally improved effects with minimal side effects; moreover, it is obvious that the combination of drugs and resveratrol must be considered. The system of naturopathy and application for natural medicine also suggests that the consumption of herbs and natural ingredients is more active during administration for a certain time, considered optimal. If this point of view is clear, then the therapeutic management and effectiveness of the therapy components are maximized. Additionally, challenges and future perspectives in resveratrol availability for cancer therapy were also recently highlighted by Ren et al. [159]
The present review highlights new evidence of resveratrol as a preventive chemical agent and a conceptual basis for a new way to prevent and treat cancer. A more broad-based approach includes synergistic combinations of different low-toxic substances, such as micro-compounds(such as resveratrol plus other therapeutic compounds) or chemo drugs which may have possible implications for several well-known and important ways in cancer therapies, angiogenesis, and metastasis. The main protein involved in carcinogenesis may be p53, as a new emphasis in the study of translation, and will define possible ways of resveratrol influence.
This article is extracted from Molecules 2021, 26, 5325. https://doi.org/10.3390/molecules26175325 https://www.mdpi.com/journal/molecules






